Nick Bayhi, PhD, Fellow

Nick Bayhi brings deep scientific expertise and hands-on venture experience spanning drug discovery, biotech industry research, and early-stage life science investing. He earned his PhD in Biophysical Sciences from the University of Chicago, where his research focused on protein conformational dynamics, using experimental and computational methods to demonstrate how structural flexibility drives protein function.

Alongside his doctoral work, Nick completed over two years of venture capital and venture creation fellowships with Insight Partners, Kendall Capital Partners, and Scion Life Sciences, leading due diligence on more than 100 startups and serving as lead author on investment memos supporting $15M in funded investments across nonviral gene delivery and antidepressant therapeutics.

Prior to graduate school, he spent five years in research roles at Genentech, ImmunoGen, and Rubius Therapeutics, applying conjugation chemistries to the development of antibody-drug conjugates and cell therapies. In addition to his role as an AN Venture Fellow, Nick serves as CEO of AddGraft Therapeutics, an autologous skin cell therapy startup.

Wendy Hung, Fellow

Wendy Hung brings a strong foundation in biomedical research and a growing track record in life science investment and business development, with expertise spanning immunology, genetic engineering, metabolism, and virology.

She is currently a fifth-year PhD candidate in Biomedical Sciences at UCSF, where her research focuses on how aging shapes immune function, with a particular emphasis on the mechanisms underlying susceptibility to infection in early life. Prior to UCSF, she conducted research at the Broad Institute.

Alongside her doctoral work, Wendy has built substantive experience across the life science investment and commercial landscape. At Novo Holdings, she contributed to the development of an investment thesis encompassing therapeutic landscape assessment, manufacturing, and operational logistics. As a Business Development intern at Mirum Pharmaceuticals, she mapped the asset landscape across multiple rare disease areas to identify unmet clinical needs. She has also advised an AI mobile health startup through key commercial milestones, contributing to a successful funding round, and has consulted for venture capital firms and nonprofits through her involvement with Biotech Connection Bay Area.